EUVIMEDEUVIMED entdecken
Open Access

Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses

Alexander D Sherry iD, Adina H Passy iD, Zachary R McCaw iD, Joseph Abi Jaoude iD, Timothy A Lin iD, Ramez Kouzy iD, Avital M Miller iD, Gabrielle S Kupferman iD, Esther J Beck iD, Pavlos Msaouel iD, Ethan B Ludmir iD

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.24.00102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Alexander D Sherry und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative findings in the field of late-phase oncology. Fitting models with prognostic covariates is a potential solution to improve power; however, the extent to which trials leverage this approach, and its impact on trial interpretation at scale, is unknown. To that end, we hypothesized that phase III trials using multivariable PEP analyses are more likely to demonstrate superiority versus trials with univariable analyses. METHODS PEP analyses were reviewed from trials registered on ClinicalTrials.gov. Adjusted odds ratios (aORs) were calculated by logistic regressions. RESULTS Of the 535 trials enrolling 454,824 patients, 69% (n = 368) used a multivariable PEP analysis. Trials with multivariable PEP analyses were more likely to demonstrate PEP superiority (57% [209 of 368] v 42% [70 of 167]; aOR, 1.78 [95% CI, 1.18 to 2.72]; P = .007). Among trials with a multivariable PEP model, 16 conditioned on covariates and 352 stratified by covariates. However, 108 (35%) of 312 trials with stratified analyses lost power by categorizing a continuous variable, which was especially common among immunotherapy trials (aOR, 2.45 [95% CI, 1.23 to 4.92]; P = .01). CONCLUSION Trials increasing power by fitting multivariable models were more likely to demonstrate PEP superiority than trials with unadjusted analysis. Underutilization of conditioning models and empirical power loss associated with covariate categorization required by stratification were identified as barriers to power gains. These findings underscore the opportunity to increase power in phase III trials with conventional methodology and improve patient access to effective novel therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicNeoplasmsHumansEndpoint DeterminationMedical OncologyMultivariate AnalysisOdds RatioPrognosis

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Insitro, South San Francisco, CA.
  • Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Department of Radiation Oncology, Stanford University, Stanford, CA.
  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Alexander D Sherry, Adina H Passy, Zachary R McCaw, Joseph Abi Jaoude, Timothy A Lin, Ramez Kouzy, Avital M Miller, Gabrielle S Kupferman, Esther J Beck, Pavlos Msaouel, Ethan B Ludmir

Förderung

  • NCI NIH HHS

Zitieren

APA

Sherry, A. D., Passy, A. H., McCaw, Z. R., Abi Jaoude, J., Lin, T. A., Kouzy, R., Miller, A. M., Kupferman, G. S., Beck, E. J., Msaouel, P., & Ludmir, E. B. (2024). Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00102

Vancouver

Sherry AD, Passy AH, McCaw ZR, Abi Jaoude J, Lin TA, Kouzy R, et al. Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00102

BibTeX
@article{Sherry2024,
  author = {Sherry, Alexander D and Passy, Adina H and McCaw, Zachary R and Abi Jaoude, Joseph and Lin, Timothy A and Kouzy, Ramez and Miller, Avital M and Kupferman, Gabrielle S and Beck, Esther J and Msaouel, Pavlos and Ludmir, Ethan B},
  title = {Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.24.00102}
}
Kostenlos starten →